Programme And Module Handbook
 
Course Details in 2026/27 Session


If you find any data displayed on this website that should be amended, please contact the Curriculum Management Team.

Module Title LH New Targets and Drugs in Cancer Therapy
SchoolCancer Studies
Department Inst of Cancer / Genomic Sci
Module Code 02 33937
Module Lead Dr Sheela Jayaraman, Deputy John Halsall
Level Honours Level
Credits 40
Semester Semester 1
Pre-requisites
Co-requisites
Restrictions It is a requirement that students achieve a mark of at least 35% in their summative exam
Contact Hours Lecture-20 hours
Tutorial-7 hours
Practical Classes and workshops-23 hours
Guided independent study-350 hours
Total: 400 hours
Exclusions
Description This module will introduce the student to state of the art efforts to identify novel targets and develop new drugs for cancer treatment. The overall structure of the module is pathology based, and the methodologies used have relevance to a wide range of diseases that have a significant impact on modern society. This module focuses on the identification and validation of targets for the treatment of cancer as this is a major killer in the UK. The module will show how expression data can be analysed by bioinformatics techniques to identify new targets and will introduce the student to modern drug development and how industry works with academia and clinicians to develop new treatments.
Learning Outcomes By the end of the module, students should be able to:
  • Demonstrate a critical understanding of the basis of current approach(es) to gene expression analysis, and the ability to interpret these data
  • Demonstrate a detailed understanding of the importance of identifying drug targets that have therapeutic relevance, and the impact of ongoing research in this area
  • Demonstrate a critical appreciation of the current experimental methodologies used to identify new targets for cancer therapy
  • Demonstrate an understanding of the principal pathological changes associated with cancer.
  • Demonstrate an advanced level of knowledge of the steps involved in validation and development of new drugs for cancer therapy
Assessment 33937-01 : Overall module mark : Mixed (100%)
Assessment Methods & Exceptions The module is assessed by a combination of a 3 hour written examination (50%) and course work (50%) - experimental data interpretation - practical write up
Reassessment:
Academic failure: If a student fails the module then they will be required to repeat the failed components only.
Failure to submit: Submission of coursework is compulsory for the programme. Students are advised that failure to submit without justifiable reason could result in failure of the module. Students will be required to submit outstanding work to meet the module outcomes.
Other
Reading List